Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CRIS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Curis Inc

CRIS
Current price
1.83 USD -0.02 USD (-1.08%)
Last closed 1.85 USD
ISIN US2312693094
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 18 936 582 USD
Yield for 12 month -73.36 %
1Y
3Y
5Y
10Y
15Y
CRIS
21.11.2021 - 28.11.2021

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Address: Building C, Lexington, MA, United States, 02421

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

16.33 USD

P/E Ratio

Dividend Yield

Financials CRIS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+10 908 000 USD

Last Year

+10 023 000 USD

Current Quarter

+2 380 000 USD

Last Quarter

+3 345 000 USD

Current Year

+10 810 000 USD

Last Year

+10 023 000 USD

Current Quarter

+2 366 000 USD

Last Quarter

+3 312 000 USD
EBITDA -42 032 000 USD
Operating Margin TTM -426.77 %
Price to Earnings
Return On Assets TTM -52.08 %
PEG Ratio
Return On Equity TTM -2 951.24 %
Wall Street Target Price 16.33 USD
Revenue TTM 11 202 000 USD
Book Value -0.63 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 14.10 %
Dividend Yield
Gross Profit TTM -26 431 000 USD
Earnings per share -6.08 USD
Diluted Eps TTM -6.08 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.059
Price Sales TTM 1.69
Enterprise Value EBITDA 0.56
Price Book MRQ 4.32

Technical Indicators CRIS

For 52 Weeks

1.02 USD 8.29 USD
50 Day MA 2.16 USD
Shares Short Prior Month 123 897
200 Day MA 3.25 USD
Short Ratio 1.24
Shares Short 110 820
Short Percent 1.06 %